Full length human recombinant protein was used as the immunogen for this recombinant NKX2.2 antibody.
Expression of NKX2.2 has been found in neuroendocrine tumors of the gut, making it a potential marker for the study of gastrointestinal neuroendocrine tumors. More recently, NKX2.2 protein was identified as a target of EWS-FLI-1, the fusion protein specific to Ewing sarcoma, and was shown to be differentially upregulated in Ewing sarcoma on the basis of array-based gene expression analysis. Antibody to NKX2.2 detects a valuable marker for Ewing sarcoma, with a sensitivity of 93% and a specificity of 89%, and aids in the differential diagnosis of small round cell tumors.
0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide
Antibody Type:
Primary Antibody
Application Verdünnung:
Immunohistochemistry (FFPE): 0.5-1ug/ml for 30 min at RT
Anwendungsbeschreibung:
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the recombinant NKX2.2 antibody to be titered up or down for optimal performance.1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
